tendonitis market insights

DelveInsight’s ‘Tendonitis - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The Tendonitis market report provides current treatment practices, emerging drugs, Tendonitis market share of the individual therapies, current and forecasted Tendonitis market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Tendonitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Tendonitis: Disease Understanding and Treatment Algorithm

Tendonitis Overview

Tendonitis is an inflammation of a tendon – a thick, flexible cord of tissue that attaches muscles to bone and assists in moving the bone or structure. Tendonitis most commonly occurs in the shoulder, bicep, elbow, hand, wrist, thumb, calf, knee, or ankle. Since the pain of tendonitis occurs near a joint, it is sometimes mistaken for arthritis. The condition is more common in adults over the age of 40 and athletes. Some forms of tendonitis are named after certain sports (e.g., tennis elbow, golfer’s elbow, pitcher’s shoulder, swimmer’s shoulder, and jumper’s knee). 

 

Tendonitis often results from sports injuries or repetitive movements. However, it can also be caused by: bad posture or walking habits; an infection; stress on soft tissues from an abnormal or poorly positioned joint or bone (such as leg length differences or joint deformities); some types of arthritis and related conditions (rheumatoid arthritis, osteoarthritis, and gout); metabolic conditions, such as diabetes; and side effects from certain medications (e.g., fluoroquinolone antibiotics and statins drugs) though this is very rare.

 

Tendonitis causes inflammation, tenderness, and pain in areas around a joint, such as the tendons, ligaments, and muscles. Some types of tendonitis can occur suddenly, last for days or longer. The pain is worse with movement and usually gets better with rest or treatment. Tendonitis symptoms can re-occur in the same area of the body.

 

Tendonitis Diagnosis

The first step in the diagnosis of tendonitis is performing a comprehensive evaluation. If there is tenderness at one specific point in the tendon, this can indicate tendonitis. If the problem does not go away with rest, ice, and over-the-counter (OTC) medications, the doctor may recommend some tests and consider all possible causes of the symptoms, and then use special imaging tests to help to get an accurate diagnosis. 

 

Medical history: The doctor asks many questions about the patient’s health history and current exercise habits and then describes the pain and how it changes with activity and rest. Physical exam: The injured area is examined by moving it in certain ways to check for areas of tenderness and test the range of motion. Attempts are made to rule out other sports injuries, such as an inflammation of the fluid-filled sacs near the tendons (bursitis). X-rays: Although X-rays do not show tendons, these tests can help rule out other medical conditions, such as bone problems. An x-ray can show calcium deposits around the tendon, which may help confirm a diagnosis. A small amount of radiation is used to make an image. Tendons cannot be seen on an X-ray, but they can show bone. 

 

Other imaging tests, such as ultrasound or MRI, may reveal swelling of the tendon sheath. Magnetic resonance imaging (MRI): If there is a partial tendon tear, MRI may be ordered to examine the area more closely. Testing for infection: On rare occasions, tendonitis can be caused by infections. The doctor may order blood tests or remove a fluid sample from the inflamed area to rule out an infection. Ultrasound: This test uses sound waves to produce images of the soft tissue structures within and around the micro-tear area. Soft-tissue structures include joints, ligaments, and tendons, which are not easy to see using other tests.

 

Tendonitis Treatment

Tendonitis may go away over time. If not, the doctor will recommend treatments to reduce pain and inflammation and preserve mobility. Severe symptoms may require specialized treatment from a rheumatologist, an orthopedic surgeon, or a physical therapist. When adequately treated, most tendonitis conditions do not result in permanent joint damage or disability. Treatment options include RICE (Rest, Ice, Compression, Elevation); physical or occupational therapy; Splints, braces, or slings – these assistive devices allow the affected area to rest until the pain eases; over-the-counter (OTC) and prescription medicines; and corticosteroids injections.

 

The goals of tendonitis treatment are to relieve pain and reduce inflammation. Often, taking care of tendonitis on its own – including rest, ice, and over-the-counter pain relievers – may be all the treatment that need. Rest: It is required to rest the injured limb or joint, at least for a short time. Failure to rest will most likely continue the symptoms. If the problem is in a hip, leg, or foot, they may need to stop stressful weight-bearing activities for a short time. This lets the inflammation lessen. Ice: Ice may help reduce inflammation and pain. Ice the area for 10–15 minutes once or twice a day. Medicine: If the pain persists, they may need non-steroidal anti-inflammatory drugs – often referred to as NSAIDs – such as aspirin, ibuprofen, or naproxen. Topical (applied to the skin) forms of NSAIDs are now available and may reduce pain and inflammation without stomach upset. In addition, acetaminophen (Tylenol) can help relieve pain.

Tendonitis Epidemiology

The Tendonitis epidemiology division provides insights into historical and current Tendonitis patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2020, the total incident cases of Tendonitis was 11.71 million cases in the 7MM which are expected to grow during the study period, i.e., 2018–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted Tendonitis epidemiology [segmented as Total incident Cases of Tendonitis, Total Gender-specific Cases of Tendonitis, Total Region-specific Cases of Tendonitis, and Total Treated Cases of Tendonitis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Tendonitis Epidemiology

• Estimates show that the highest cases of Tendonitis in the 7MM were in the United States, followed by Japan, France, the United Kingdom, Italy, Germany, and Spain in 2020.
• In the United States, the total number of incident cases of Tendonitis was 4.77 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
• In the year 2020, the total incident cases of Tendonitis were 0.17 million cases in Spain which are expected to grow during the study period, i.e., 2018–2030.
• In Japan, the total number of incident cases of Tendonitis was 1.99 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

Tendonitis Drug Chapters

The drug chapter segment of the Tendonitis report encloses the detailed analysis of Tendonitis marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Tendonitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Tendonitis Emerging Drugs

 

AmnioFix (MiMedX group) 

AmnioFix, developed by the MiMedX group, is a dehydrated human amnion/chorion membrane allograft available in sheet, particulate, and wrap configurations in various sizes to reduce wastage. It is a semi-permeable protective barrier membrane product comprised of a dehydrated human amnion/chorion membrane that may be used to treat wounds related to surgical procedures. The product is derived from donated C-sections of live births in the US and undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.

 

Amniotic Fluid Tissue: R3 Stem Cell

Amniotic stem cells are derived from amniotic fluid obtained during scheduled cesarean sections from consenting donors. Amniotic fluid surrounds the fetus during pregnancy, feeding it. Usually, this fluid is discarded, but it can be used for those in need because of its unique ingredients. Researchers have discovered that the amniotic fluid has an extremely high concentration of regenerative cells, even more than bone marrow in adults.

 

Ortho-ATI (Ortho Cell) 

Orthocell’s Autologous Tenocyte Implantation (Ortho-ATI) is a new tissue engineering technique designed to assist and improve the regeneration of the damaged/injured tendon. It involves a biopsy procedure where a small tendon is harvested from a healthy tendon (typically the tendon below the kneecap). The biopsied tissue is sent to Orthocell’s specially designed and government-regulated laboratory, where the building blocks of the tendon, the tenocyte cells, are isolated and grown over approximately 4–5 weeks. The cells are then implanted via injection into the affected tissue via ultrasound guidance. The therapy addresses the underlying pathology of tendon injury, replenishing degenerative tissue with healthy mature tendon cells. This unique treatment uses each patient’s tendon-derived cells to stimulate tendon regeneration and is delivered via ultrasound-guided injection under local anesthetic. 

 

Adipose-derived regenerative cells (InGeneron)

Adipose-derived regenerative cells (ADRC) are a population of cells derived from adipose tissue with stem cell and wound repair activities. ADRC consists of several cell types: adult stem cells, vascular endothelial cells, and vascular smooth muscle cells. These cells contribute to wound repair through various mechanisms by promoting blood vessel growth and blocking apoptosis. In addition, ADRC can differentiate into several tissue types, such as bone, cartilage, fat, skeletal muscle, smooth muscle, and cardiac muscle. During the process, adipose tissue is removed under local anesthesia from the patient’s abdominal area, and the adipose-derived regenerative cells are isolated from the sample using a centrifuge and an enzyme. Then the cells are washed, filtered, and injected back into the patient’s shoulder. 

Note: Detailed emerging therapies assessment will be provided in the final report.

Tendonitis Market Outlook 

The goals of tendonitis treatment are to relieve the pain and reduce inflammation. The self-care of tendonitis includes rest, ice, and over-the-counter (OTC) pain relievers. This method helps decrease inflammation and swelling and brings temporary pain relief. This type of conservative treatment is generally all that is necessary to recover from true tendonitis. Tendonitis usually resolves itself in a few days to a few weeks. However, long-term tendinopathy may take 2–6 months to heal. Many tendon injuries become chronic problems that gradually worsen because the athlete continues the activity despite the nagging pain (Quinn, 2020).

 

Pain relievers including aspirin, naproxen sodium (Aleve), or ibuprofen (Advil, Motrin IB, others) may relieve discomfort associated with tendonitis. Topical creams with anti-inflammatory medication – popular in Europe and becoming increasingly available in the United States – also may be effective in relieving pain without the potential side effects of taking anti-inflammatory medications by mouth. Corticosteroids may be injected around a tendon to relieve tendonitis; injections of cortisone – naturally occurring corticosteroids – reduce inflammation and can help ease the pain. 

 

Platelet-rich plasma (PRP) is a well-known therapy for the treatment of tendinopathy. It involves taking a blood sample and spinning the blood to separate the platelets and other healing factors. The solution is then injected into the area of chronic tendon irritation. Physical therapy is also beneficial and includes specific exercises designed to stretch and strengthen the affected muscle-tendon unit.

 

In situations where physical therapy has not resolved symptoms, surgical methods are recommended, including dry needling, which involves making small holes in the tendon with a fine needle to stimulate factors involved in tendon healing. Positive effects of the ultrasonic treatment on tendon healing have been observed, supported by solid evidence. It uses a small incision to insert a special device that removes tendon scar tissue with ultrasonic sound waves (Mayo Clinic, n.d.). 

 

If tendonitis persists and there are calcium deposits around the tendon, extracorporeal shock wave therapy (ESWT) may help. In this method, a shock wave is passed through the skin, breaking up the calcium deposits. The deposits may also be removed surgically.

 

In the current scenario, two products are available in the market. Apart from these, several patches and devices are also available. 

 

Ostenil Tendon, developed by TRB Chimedica, is a highly concentrated hyaluronic acid (2%). Hyaluronic acid is present in the body wherever moisture is stored, or lubrication between layers of tissue is required to eliminate friction. Ostenil tendon was developed to treat pain and restricted mobility in tendon disorders caused, for example, by overuse or inappropriate biomechanical stress. It contains 40 mg /2 mL sodium hyaluronate, plus mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. It was developed with the active cooperation of German orthopedic and trauma surgeons and was CE certified as a medical device in 2011 for the treatment of pain and reduced mobility in tendon disorders.

 

VergenixSTR (CollPlant) is a soft tissue repair matrix that combines cross-linked rhCollagen with PRP, a concentrated blood plasma that contains high levels of platelets, a critical component of the healing process. VergenixSTR serves as a scaffold to support cell proliferation and the release of growth factors. The product is injected into the affected area and forms a viscous gel matrix which serves as a temporary reservoir for PRP in the vicinity of a tendon injury site, holding the platelet concentrate in place at the injured area. In 2016, VergenixSTR received a CE Mark for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons, including the elbow tendon (tennis elbow), rotator cuffs, patellar tendons, Achilles tendon, and hand tendon.

 

However, as discussed previously, the current treatment options pose several challenges, and the tendons are not able to heal properly. In short, efficacious pharmacologic options for managing tendonitis are limited. Recently some developmental initiatives have been taken towards the management of tendonitis. Some interesting therapies are in the pipeline with companies like MiMedx Group, OrthoCell, Causeway Therapeutics, R3 Stem Cell, and others investigating novel targeted treatment options for tendonitis.

 

Key Findings

The Tendonitis market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Tendonitis in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 2.9%. According to the estimates, the highest market size of Tendonitis is found in the United States followed by Japan.

 

The United States Market Outlook

The total market size of Tendonitis therapies in the United States is expected to increase with a CAGR of 4.3% in the study period (2018–2030).

 

EU-5 Countries: Market Outlook

The total market size of Tendonitis therapies in EU-5 countries is expected to increase with a CAGR of 0.4% in the study period (2018–2030).

Japan Market Outlook

The total market size of Tendonitis therapies in Japan is expected to increase with a CAGR of 0.3% in the study period (2018–2030).

Tendonitis Pipeline Development Activities 

The drugs which are in pipeline include: 

• AmnioFix (Micronized DHACM): MiMedx Group
• Amniotic Fluid Tissue: R3 Stem Cell
• Ortho-ATI: Orthocell
• Adipose-Derived Regenerative Cells: InGeneron 

Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary

Increased patient pool and novel treatment approaches play an important role in the development of the market of Tendonitis is expected to increase in the forecast period.

KOL-Views 

To keep up with current market trends, we take KOLs and SMEs ’ opinions working in the Tendonitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Tendonitis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 

Competitive Intelligence Analysis 

We perform a Competitive and Market Intelligence analysis of the Tendonitis Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

• The report covers the descriptive overview of Tendonitis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight has been provided into the Tendonitis epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Tendonitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Tendonitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Tendonitis market.

Report Highlights

• In the coming years, the Tendonitis market is set to change due to the upcoming therapies with the novel mechanism of action which are under investigation and ongoing research in the Tendonitis; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Tendonitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Tendonitis. The launch of emerging therapies will significantly impact the Tendonitis market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Tendonitis.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Tendonitis Report Insights

• Patient Population
• Therapeutic Approaches
• Tendonitis Pipeline Analysis
• Tendonitis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Tendonitis Report Key Strengths

• 10 Years Forecast
• 7MM Coverage 
• Tendonitis Epidemiology Segmentation
• Key Cross Competition 
• Highly Analyzed Market
• Drugs Uptake

Tendonitis Report Assessment

• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Tendonitis Market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the Tendonitis total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
• What are the key findings of the market across the 7MM and which country will have the largest Tendonitis market size during the study period (2018–2030)?
• At what CAGR, the Tendonitis market is expected to grow in the 7MM during the study period (2018-2030)?
• What would be the Tendonitis market outlook across the 7MM during the study period (2018–2030)?
• What would be the Tendonitis market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• Tendonitis patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Tendonitis market?

 

Epidemiology Insights:

• What are the disease risks, burdens, and unmet needs of Tendonitis?
• What is the historical Tendonitis patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What would be the forecasted patient pool of Tendonitis in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Tendonitis?
• Out of all the 7MM countries, which country would have the highest incident population of Tendonitis during the study period (2018–2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Tendonitis?

 

Current Treatment Scenario and Emerging Therapies:

• What are the current options for the treatment of Tendonitis?
• What are the current treatment guidelines for the treatment of Tendonitis in the US, Europe, and Japan?
• How many companies are developing therapies for the treatment of Tendonitis?
• How many therapies are developed by each company for the treatment of Tendonitis?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Tendonitis?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tendonitis therapies? 
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Tendonitis and their status?
• What are the key designations that have been granted for the emerging therapies for Tendonitis?
• What is the global historical and forecasted market of Tendonitis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Tendonitis market.
• To understand the future market competition in the Tendonitis market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Tendonitis in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Tendonitis market.
• To understand the future market competition in the Tendonitis market.